Prescribing Information
... PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obs ...
... PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA), or shift work disorder (SWD). Limitations of Use In OSA, PROVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obs ...
full prescribing information in pdf format
... sleep that occur almost daily for at least three months, plus sudden bilateral loss of postural muscle tone in association with intense emotion (cataplexy) or 2) a complaint of excessive sleepiness or sudden muscle weakness with associated features: sleep paralysis, hypnagogic hallucinations, automa ...
... sleep that occur almost daily for at least three months, plus sudden bilateral loss of postural muscle tone in association with intense emotion (cataplexy) or 2) a complaint of excessive sleepiness or sudden muscle weakness with associated features: sleep paralysis, hypnagogic hallucinations, automa ...
A Systematic Review of Modafinil: Potential
... Background: Modafinil is a novel wakepromoting agent that has U.S. Food and Drug Administration approval for narcolepsy and shift work sleep disorder and as adjunctive treatment of obstructive sleep apnea/hypopnea syndrome. Modafinil has a novel mechanism and is theorized to work in a localized mann ...
... Background: Modafinil is a novel wakepromoting agent that has U.S. Food and Drug Administration approval for narcolepsy and shift work sleep disorder and as adjunctive treatment of obstructive sleep apnea/hypopnea syndrome. Modafinil has a novel mechanism and is theorized to work in a localized mann ...
Modafinil attenuates reinstatement of cocaine seeking: role for
... Modafinil may be useful for treating stimulant abuse, but the mechanisms by which it acts to do so are unknown. Indeed, a primary effect of modafinil is to inhibit dopamine transport, which typically promotes rather than inhibits motivated behavior. Therefore, we examined the role of nucleus accumbe ...
... Modafinil may be useful for treating stimulant abuse, but the mechanisms by which it acts to do so are unknown. Indeed, a primary effect of modafinil is to inhibit dopamine transport, which typically promotes rather than inhibits motivated behavior. Therefore, we examined the role of nucleus accumbe ...
alertec - Shire Canada
... reported in adults and children in association with the use of modafinil. Modafinil is not approved for use in pediatric patients for any indication. In clinical trials of modafinil, the incidence of rash resulting in discontinuation was approximately 0.8% (13 per 1,585) in pediatric patients (age < ...
... reported in adults and children in association with the use of modafinil. Modafinil is not approved for use in pediatric patients for any indication. In clinical trials of modafinil, the incidence of rash resulting in discontinuation was approximately 0.8% (13 per 1,585) in pediatric patients (age < ...
modafinil - Awake Institute, LLC
... ability to sleep at night. In Europe, modafinil has been used since at least 1988 to treat narcolepsy and idiopathic hypersomnolence. Following two large, multicenter trials, Provigil was approved by the FDA in the U.S. in December 1998 for the treatment of narcolepsy. The use of the drug is rapidly ...
... ability to sleep at night. In Europe, modafinil has been used since at least 1988 to treat narcolepsy and idiopathic hypersomnolence. Following two large, multicenter trials, Provigil was approved by the FDA in the U.S. in December 1998 for the treatment of narcolepsy. The use of the drug is rapidly ...
Modafinil decreases anxiety-like behaviour in zebrafish
... Modafinil (2-((diphenylmethyl)sulfinyl)acetamide), a selective dopamine and norepinephrine transporter inhibitor, is most commonly prescribed for narcolepsy but has gained recent interest for treating a variety of disorders. Zebrafish (Danio rerio) are becoming a model of choice for pharmacological ...
... Modafinil (2-((diphenylmethyl)sulfinyl)acetamide), a selective dopamine and norepinephrine transporter inhibitor, is most commonly prescribed for narcolepsy but has gained recent interest for treating a variety of disorders. Zebrafish (Danio rerio) are becoming a model of choice for pharmacological ...
Emerging treatment options for excessive sleepiness associated
... cataplexy attacks, night-time awakenings, and inadvertent daytime naps, and reduced daytime sleepiness as determined by the ESS [24]. This effect was maintained when sodium oxybate was administered in a 12-month, open-label study [25]. The improvements in sleepiness with sodium oxybate may be relate ...
... cataplexy attacks, night-time awakenings, and inadvertent daytime naps, and reduced daytime sleepiness as determined by the ESS [24]. This effect was maintained when sodium oxybate was administered in a 12-month, open-label study [25]. The improvements in sleepiness with sodium oxybate may be relate ...
Product Information - Therapeutic Goods Administration
... in rats. In addition, alpha-methyl-p-tyrosine, a dopamine synthesis inhibitor, blocks the action of amphetamine, but does not block locomotor activity induced by modafinil. In addition to its wake-promoting effects and ability to increase locomotor activity in animals, modafinil produces psychoactiv ...
... in rats. In addition, alpha-methyl-p-tyrosine, a dopamine synthesis inhibitor, blocks the action of amphetamine, but does not block locomotor activity induced by modafinil. In addition to its wake-promoting effects and ability to increase locomotor activity in animals, modafinil produces psychoactiv ...
The Effects of Modafinil Treatment on Neuropsychological and
... in treatment outcomes for MA-dependent patients; however, the benefits to cognition function, which is critical to treatment success but known to be impaired, has yet to be examined. The first 20 participants recruited to the study were administered either 200 mg of modafinil (once daily) or placebo ...
... in treatment outcomes for MA-dependent patients; however, the benefits to cognition function, which is critical to treatment success but known to be impaired, has yet to be examined. The first 20 participants recruited to the study were administered either 200 mg of modafinil (once daily) or placebo ...
Modafinil - North East Sleep Society
... The prevalence of psychosis, psychiatric hospitalizations, tachyarrhythmias, polysubstance abuse, anorexia and weight loss were significantly increased in the stimulant group. ...
... The prevalence of psychosis, psychiatric hospitalizations, tachyarrhythmias, polysubstance abuse, anorexia and weight loss were significantly increased in the stimulant group. ...
Modafinil Bluefish Tablet ENG SmPC
... population) a normally ancillary metabolic pathway involving CYP2C19 becomes more important. As modafinil may inhibit CYP2C19, lower doses of antidepressants may be required in such patients. Anticoagulants: Due to possible suppression of CYP2C9 by modafinil the clearance of warfarin may be decrease ...
... population) a normally ancillary metabolic pathway involving CYP2C19 becomes more important. As modafinil may inhibit CYP2C19, lower doses of antidepressants may be required in such patients. Anticoagulants: Due to possible suppression of CYP2C9 by modafinil the clearance of warfarin may be decrease ...
name of the candidate and address
... Modafinil and its effect on CVS parameters Modafinil has been known to exert an effect on cardiovascular system. Taneja et al. in 2005, found that Modafinil increases resting heart rate (9.2±2.0 bpm; [mean ±SE], resting systolic blood pressure (SBP) (7.3±3.2 mm Hg), and resting diastolic blood press ...
... Modafinil and its effect on CVS parameters Modafinil has been known to exert an effect on cardiovascular system. Taneja et al. in 2005, found that Modafinil increases resting heart rate (9.2±2.0 bpm; [mean ±SE], resting systolic blood pressure (SBP) (7.3±3.2 mm Hg), and resting diastolic blood press ...
Retrospective Review of Trend in Modafinil Overexposures
... hippocampus and thalamus (11). Additionally, it is known to increase extracellular concentrations of dopamine, norepinephrine, serotonin, glutamate, and histamine (11). However, unlike the amphetamines, modafinil does not have an effect on spontaneous dopamine release. The standard therapeutic dose ...
... hippocampus and thalamus (11). Additionally, it is known to increase extracellular concentrations of dopamine, norepinephrine, serotonin, glutamate, and histamine (11). However, unlike the amphetamines, modafinil does not have an effect on spontaneous dopamine release. The standard therapeutic dose ...
Armodafinil-and-Modafinil-Safety-Series
... available since the late 1970’s. However, they have only become commonly known since the Food and Drug Administration (FDA) approved Modafinil under the brand name Provigil in 1998. Adrafinil (Pronounced ah DRAF i nil) The first commonly available Eugeroic was Adrafinil. It was invented by the Frenc ...
... available since the late 1970’s. However, they have only become commonly known since the Food and Drug Administration (FDA) approved Modafinil under the brand name Provigil in 1998. Adrafinil (Pronounced ah DRAF i nil) The first commonly available Eugeroic was Adrafinil. It was invented by the Frenc ...
Modafinil And Armodafinil Safety Guide
... available since the late 1970’s. However, they have only become commonly known since the Food and Drug Administration (FDA) approved Modafinil under the brand name Provigil in 1998. Adrafinil (Pronounced ah DRAF i nil) The first commonly available Eugeroic was Adrafinil. It was invented by the Frenc ...
... available since the late 1970’s. However, they have only become commonly known since the Food and Drug Administration (FDA) approved Modafinil under the brand name Provigil in 1998. Adrafinil (Pronounced ah DRAF i nil) The first commonly available Eugeroic was Adrafinil. It was invented by the Frenc ...
Modafinil Enhances Two-Year Outcome from Monoamine Oxidase
... therapy and vagal nerve stimulation. All patients had reported feeling some improvement before the addition of modafinil to existing MAOI therapy. However, immobilizing exhaustion in the 2 male patients and fatigue in the female patient impaired daily function. All patients suffered multiple serious ...
... therapy and vagal nerve stimulation. All patients had reported feeling some improvement before the addition of modafinil to existing MAOI therapy. However, immobilizing exhaustion in the 2 male patients and fatigue in the female patient impaired daily function. All patients suffered multiple serious ...
(PSD) March 2016 PBAC Meeting
... The resubmission stated that rates of withdrawal from modafinil therapy indicates that there is a clinical need for more than one medication in the therapeutic area, with armodafinil having been shown in long-term studies to provide an effective and tolerable option for some patients. For more detai ...
... The resubmission stated that rates of withdrawal from modafinil therapy indicates that there is a clinical need for more than one medication in the therapeutic area, with armodafinil having been shown in long-term studies to provide an effective and tolerable option for some patients. For more detai ...
Modafinil for Narcolepsy - Amber Shared Care ESHUT
... It is recommended that modafinil tablets not be used in patients with a history of left ventricular hypertrophy or cor pulmonale. Modafinil should not be used in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants Patie ...
... It is recommended that modafinil tablets not be used in patients with a history of left ventricular hypertrophy or cor pulmonale. Modafinil should not be used in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants Patie ...
MODAFINIL for excessive sleepiness
... mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. This syndrome may present with ischaemic ECG changes, chest pain or arrhythmia. Patients should be advised that modafinil is not a replacement for sleep and good sleep hygiene shou ...
... mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants. This syndrome may present with ischaemic ECG changes, chest pain or arrhythmia. Patients should be advised that modafinil is not a replacement for sleep and good sleep hygiene shou ...
Modafinil manufacturers in India, cas. No. 68693
... medications called wakefulness promoting agents. It works by changing the amounts of certain natural substances in the area of the brain that controls sleep and wakefulness. How should this medicine be used? Modafinil comes as a tablet to take by mouth. It is usually taken once a day with or without ...
... medications called wakefulness promoting agents. It works by changing the amounts of certain natural substances in the area of the brain that controls sleep and wakefulness. How should this medicine be used? Modafinil comes as a tablet to take by mouth. It is usually taken once a day with or without ...
FACT SHEET: Stimulants
... mechanisms of action include the inhibition of dopamine reuptake (a feature shared by cocaine and methylphenidate), the activation of glutamate and orexin, the inhibition of GABA (a major inhibitory neurotransmitter), and the blockade of norepinephrine reuptake in the sleep promoting center of the b ...
... mechanisms of action include the inhibition of dopamine reuptake (a feature shared by cocaine and methylphenidate), the activation of glutamate and orexin, the inhibition of GABA (a major inhibitory neurotransmitter), and the blockade of norepinephrine reuptake in the sleep promoting center of the b ...
PPT
... increase the circulating levels of those compounds and dose adjustments maybe necessary. • Co-administration of modafinil with other CNS active drugs such as methylphenidate and dextroamphetamine did not significantly alter the pharmacokinetics of either drug. ...
... increase the circulating levels of those compounds and dose adjustments maybe necessary. • Co-administration of modafinil with other CNS active drugs such as methylphenidate and dextroamphetamine did not significantly alter the pharmacokinetics of either drug. ...
Modafinil
Modafinil is a wakefulness-promoting agent (or eugeroic) used for treatment of wakefulness disorders such as narcolepsy, shift work sleep disorder, and excessive daytime sleepiness associated with obstructive sleep apnea. In English-speaking countries it is sold under the brand names: Alertec (CA), Modavigil (AU, NZ), and Provigil (IE, ZA, UK, US).